The FDA approved selumetinib as treatment for pediatric neurofibromatosis type 1, expanding options for young patients with inoperable plexiform neurofibromas.
Approval Alert | Selumetinib in Pediatric NF1-PNs
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Pembrolizumab Formulation in Solid Tumors
2
Cevostamab Post-CAR T-Cell Therapy is Safe in Heavily Pretreated Multiple Myeloma
3
Advancing AI in Oncology: Critical Considerations for Clinical Practice
4
Cevostamab Combo Shows Enduring Responses in R/R Multiple Myeloma
5
